semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Type1 Diabetes Mellitus Type 1 Diabetes Mellitus for more than 12 months BMI between 18.5 and 28.5 kg/m² HbA1C level <=9.0% Insulin treated for at least 12 months with total insulin dose <1.2U/kg/day  Type 2 Diabetes Mellitus History of multiple and/or severe allergies to drugs or foods Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological (with the exception of conditions associated with diabetes mellitus), haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness as judged by the Investigator More than one episode of severe hypoglycaemia with seizure, coma or requiring assistance of another person during the past 6 months Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular autonomic neuropathy Females of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant or are not using highly effective contraceptive methods
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 60.0-80.0,  Vitamin D Deficiency Diabetes Mellitus Hypertension Lipid Metabolism Disorders Obesity, Abdominal Food insecure Have fit of metabolic syndrome; (WC>90 cm), obesity (BMI≥30 kg/m2), diabetes (FBS>100 mg/dl), high blood pressure (systolic >135 mmHg and diastolic >85 mmHg) and dyslipidaemia (LDL≥ 240 mg/dl, HDL<40 mg/dl, TC≥ 160 mg/dl; TG≥ 200 mg/dl) Vitamin D deficient; serum 25(OH) D level <30 ng/ml No use of vitamin D supplementation before 60 days  An inability or unwillingness to participate Those who are already taking any type of vitamin D supplements Individuals with a history of allergy Those subjects with serious medical condition such as cancer, heart attack, stroke, and etc Illness that required corticosteroids or insulin Drugs are known to influence vitamin D level; steroids, anti-acids, oestrogen People with conditions that contradict vitamin D supplementation, for example, a history of hypercalcaemia, hepatic disease or renal stones, sarcoidosis, or malignancy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections Stage 1 Age 18 years or above Born biological male Self-identifies as MSM or transgender woman Thai citizen Resident in Bangkok or surrounding suburb Had sex with a male partner at least once in the previous 12 months Consents to participate in the study  Unable to perform any study procedures, or unable to commit to attend all study visits Has a serious medical, psychological, or substance use problem that, in the opinion of the study staff, would prevent appropriate participation or adequate follow-up in the trial Stage 2 Must meet all of the in stage 1, plus Completed HIV test with result determined to be positive or negative Agrees to return for follow-up visits with testing per protocol every 6 months for 18 months Consents to participate in the study Indeterminate HIV test result
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 35.0-65.0,  Type 2 Diabetes Mellitus Obesity Patients with type 2 diabetes who are overweight and obese (BMI 25-50 kg/m2), 35 to 65 years of age, and sedentary (<60 minutes structured exercise/week). Healthy volunteers without type 2 diabetes: 35 to 65 years of age  Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke; 2. renal or hepatic diseases; 3. active cancer; 4. autoimmune diseases; 5. immunosuppressant therapy; 6. excessive alcohol consumption (>14 drinks/week for men; >7 drinks/week for women); 7. current tobacco use; 8. pregnancy; 9. mobility limitations; 10. foot ulcers; 11. diabetic neuropathy 12. uncontrolled hypertension (>=180 systolic / 100 diastolic mmHg)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Type 2 Diabetes Mellitus Dyslipidemias normal group: body mass index [BMI]<23kg/m2, without diabetes mellitus history prediabetes group: fasting blood glucose ≥100 mg/dL and <126 mg/dL or postprandial blood glucose ≥140 mg/dL and <200 mg/dL type 2 diabetes according to ADA(American Diabetes Association) guideline (1) fasting blood glucose ≥126 mg/dL, (2) random blood glucose ≥200 mg/dL and with typical diabetes symptoms, (3) glycated hemoglobin A1c ≥6.5% and anti-hypoglycemic drug naive patients with type 2 diabetes, metformin monotherapy, SGLT2 inhibitor monotherapy patients with dyslipidemia, ezetimibe therapy  inflammatory bowel disease (Crohn's disease, ulcerative colitis) history of stomach, small intestine or colon resection operation on antibiotics therapy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 25.0-70.0,  Type1diabetes Hypoglycemia Unawareness Nocturnal Hypoglycemia Hypoglycemia Night Hypoglycemia Male and female subjects age 25 to 70 years Subjects who are able to provide written informed consent and to comply with the procedures of the study protocol Clinical history compatible with type 1 diabetes with disease onset < 40 years of age and insulin dependent for > 10 years Absent C-peptide (< 0.3 ng/ml) Involvement in intensive diabetes management defined as the use of basal-bolus insulin analog delivery by multi-dose injection (MDI) or continuous subcutaneous insulin infusion (CSII) together with self-monitoring of blood glucose values more than 3 times daily with or without continuous glucose monitoring (CGM) under the direction of an endocrinologist, diabetologist, or diabetes nurse practitioner with at least 3 clinical evaluations during the previous 12 months Hypoglycemia unawareness manifested by a Clarke score of 4 or more AND at least 1 of the following: HYPO score greater than or equal to the 90th percentile (1047); OR marked glycemic lability defined by a glycemic lability index (LI) score greater than or equal to the 90th percentile (433 mmol/l2/h•wk-1); OR a composite of a HYPO score greater than or equal to the 75th percentile (423) and a LI greater than or equal to the 75th percentile (329) (Senior et al., 2015) Documented > 5% time spent in the hypoglycemic range (glucose < 60 mg/dl) by 7 day real time or blinded CGM; at least one episode of hypoglycemic during the 7 days must occur overnight  BMI ≥ 30 kg/m2 Insulin requirement of ≥ 1.0 units/kg•day HbA1c ≥ 10% Untreated proliferative diabetic retinopathy Uncontrolled hypertension: systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg Active cardiovascular disease Abnormal kidney function: eGFR < 60 ml/min/1.73 m2 Abnormal liver function: persistent elevation of liver function tests > 1.5 times the upper limit of normal Untreated hypothyroidism, Addison's disease, or Celiac disease Anemia: baseline hemoglobin concentration < 11 g/dl in women and < 12 g/dl in men
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnea Respiratory Failure patients who presented with acute dyspnea in the ED patients who had an ABG analysis as part of the ED standard management  Patients with treatment limitation decisions made by the medical teams against ICU admission, including severe cognitive impairment or palliative care  Patients with immediate transfer to ICU due to shock and hemodynamic instability at ED admission
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Copd Inspiratory Muscle Weakness Clinical Diagnosis of COPD Inspiratory Muscle Weakness (Pi,max <70% predicted or < 60 cmH2O) Baseline dyspnea index (BDI) < 7 Peripheral muscle fatigue present after CPET  Major cardiovascular Limiting exercise capacity more than pulmonary function impairment Severe orthopedic with major impact on daily activities Psychiatric or cognitive disorders Progressive neurological or neuromuscular disorders Longterm O2 therapy Previous in rehabilitation program (<1 year)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Heart Failure Heart Failure Acute Acute Cardiac Failure Acute Cardiac Pulmonary Edema Age ≥ 21 years Presents with shortness of breath at rest or with minimal exertion Clinical diagnosis of AHF and presence of > 15 total bilateral B-lines distributed in at least 4 zones on initial LUS Hx of chronic HF and ANY ONE OF THE [Chest radiograph consistent with AHF Jugular venous distension Pulmonary rales on auscultation Lower extremity edema BNP > 500pg/mL]  Chronic renal dysfunction, including ESRD or eGFR < 20 ml//min/1.73m2 Shock of any kind. Any requirement for vasopressors or inotropes SBP < 120 Need for immediate intubation Acute Coronary Syndrome OR new ST-segment elevation/depression on EKG. (troponin release outside of ACS is allowed) Fever >101.5ºF End stage HF: transplant list, ventricular assist device Anemia requiring transfusion Known interstitial lung disease Suspected acute lung injury or acute respiratory distress syndrome (ARDS)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cardiac Amyloidosis Have a parietal thickness measuring more than 15 mm on the echocardiography or have structural and echogenicity abnormalities characteristic of cardiac amyloidosis Live in Martinique Accept the use of the residues coming from biopsies of the subcutaneous abdominal adipose tissue performed during the medical care  Be under 18 years old Have a contraindication to subcutaneous biopsy Be allergic to local anesthetics Pregnant or nursing woman Have a cardiovascular disease suggesting a secondary cardiac disease, such as documented severe hypertension, valvular stenosis, or a known familial cardiomyopathy Be major under guardianship / curatorship or deprived of liberty Not be able to answer to a simple administrative questionnaire or to give freely its non-opposition
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-75.0,  Type2 Diabetes Male subjects with type 2 diabetes between the age of 20-75 years who can speak and understand Arabic or English Female subjects with type 2 diabetes between the age of 20-75 years who can speak and understand Arabic or English Patients must be on any basal insulin (once daily) Patients must be on any basal insulin (twice daily) Patients on stable dose of oral antidiabetes drugs can be included (No change in the dose for the previous 12 weeks) Body Mass Index <40kg/m2 Subjects who have signed informed consent form Patients will be fasting during Ramadan  Type 1 diabetes Type 2 diabetes on a basal bolus regimen or those on premix insulin or on self-mix insulin On GLP-1 receptor agonists medication On glinide medication Ischaemic heart disease Left bundle branch block on ECG Active diabetic retinopathy or maculopathy requiring acute treatment Unwilling to follow the protocol Pregnancy, intention to become pregnant, breastfeeding
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-95.0,  Acute Coronary Syndrome Depressive Disorder Anxiety Disorders Stress Disorders, Post-Traumatic New Brunswick, Ontario and Quebec sites: 1. men with a diagnosis of ACS (Acute cardiac syndrome) : myocardial infarction such as ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina, or angioplasty with or without a stent or coronary bypass in the last 3 months. 2. able to speak or write in English or French 3. with an identified treating health professional (cardiologist, family doctor or nurse practitioner). 4. able to attend 8 weekly sessions if qualifies for step 2; 5. available for at least one year of follow-up New-Brunswick site only: 1. Surgery patients (surgery in the last three months) will also be included (CABG, Percutaneous valve, Valve, Valve/Graft, Cardioverter (pacemaker), …) 2. Congestive heart failure : patients with NYHA Class III or NYHA Class IV  Abuse of any substance in the past 12 months such as alcohol, cannabis, drugs as screened by the Simple Screening Instrument for Substance Abuse Self-reported personal history of psychotic disorders or bipolar disorders (i.e. schizophrenia, paranoia, personality disorders Recently (3 months or less) started on psychotherapy or pharmacological treatment of MD/AD/TRS
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 2 Diabetes Treated With Insulin Men or woman Age ≥ 18 years old Patient with type 2 diabetes, treated with insulin for at least one year Patient accepting to participate to the study  • Pregnant or breastfeeding woman
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnea Malignant Neoplasm Diagnosis of cancer Dyspnea with an average intensity >= 4 on the dyspnea NRS (range 0-10) over the past week Radiologic suspicion of thoracic involvement, such as primary or metastatic lung cancer, lymphangitic carcinomatosis, airway infiltration, lymphadenopathy, pleural or chest wall invasion Seen at an outpatient clinic at MD Anderson Cancer Center or Lyndon B. Johnson (LBJ) Hospital General Oncology Clinic Able to communicate in English or Spanish Karnofsky performance status >= 30%  Delirium (i.e., score > 13 on the Memorial Delirium Assessment Scale; range 1-30) Oxygen saturation < 90% despite supplemental oxygen > 6 L/minute Previous allergic reactions to dexamethasone Diagnosis of diabetes mellitus uncontrolled with oral hypoglycemic agents or insulin Postsurgical open wound that has not healed at the time of enrollment Any infection requiring antibiotics at the time of study enrollment Major surgery within the past 2 weeks Megestrol use at the time of study enrollment Neutropenia (absolute neutrophil count < 1.0 x 10^9/L) at the time of study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks) Currently receiving or expected to start cytotoxic chemotherapy or immunotherapy within 1 week of study enrollment and additional dexamethasone cannot be used concurrently as per attending oncologist